FOLFIRI Regimen Adverse Drug Reactions and Incidence Rates
The FOLFIRI regimen (irinotecan, leucovorin, and 5-fluorouracil) demonstrates a well-characterized toxicity profile with neutropenia (20-52%), diarrhea (12-61%), and gastrointestinal toxicities being the most prominent adverse reactions.
Regimen Composition
The standard FOLFIRI regimen consists of 1:
- Irinotecan: 180 mg/m² IV over 30-90 minutes, day 1
- Leucovorin: 400 mg/m² IV infusion matching irinotecan duration, day 1
- 5-FU: 400 mg/m² IV bolus day 1, then 1200 mg/m²/day × 2 days (total 2400 mg/m² over 46-48 hours) continuous infusion
- Cycle: Repeated every 2 weeks
Hematologic Adverse Reactions
Neutropenia
- Grade 3-4 neutropenia: 20-52% 2, 3, 4
- All-grade neutropenia: 21.6-72.7% 5, 6
- Febrile neutropenia: Significantly increased with FOLFIRI versus doublet chemotherapy 7
Other Hematologic Toxicities
- Leukopenia: 15.6-21% (grade 3-4) 8, 2
- Thrombocytopenia: 18.1-31.8% (all grades) 9
- Anemia: 19-30% (grade 2-4) 2, 3
Gastrointestinal Adverse Reactions
Diarrhea
- Grade 3-4 diarrhea: 12-20.5% 2, 10, 8
- All-grade diarrhea: 61.2% 5
- Significantly increased compared to single-agent irinotecan (6.2% vs lower rates) 4
Other GI Toxicities
- Nausea: 16.2% (all grades) 6
- Vomiting: 11-58.2% (all grades) 10, 5
- Anorexia: 91.4% (all grades) 5
- Mucositis/Stomatitis: 5.2-40.9% 5, 4
- Constipation: 47.8% 5
Non-Hematologic Adverse Reactions
Fatigue/Asthenia
Dermatologic
- Alopecia: 71.6% (all grades) 5
- More prominent with irinotecan-containing regimens compared to oxaliplatin-based regimens 11, 10
Other Toxicities
Comparative Toxicity Profile
FOLFIRI demonstrates distinct toxicity patterns compared to FOLFOX 11, 10:
- More common with FOLFIRI: Alopecia, diarrhea, febrile neutropenia
- More common with FOLFOX: Peripheral neuropathy, less diarrhea
Treatment-Related Mortality
- Treatment-related deaths: Rare but reported, including neutropenic sepsis and hypotension/shock 3, 8
- Grade 5 adverse events: Approximately 1.0% in real-world settings 6
Special Considerations
UGT1A1 Polymorphisms
Patients with UGT1A1 genetic polymorphisms (Gilbert syndrome or elevated bilirubin) require dose reduction and careful monitoring due to increased risk of severe irinotecan toxicity 12.
Age-Related Toxicity
In elderly patients (≥75 years), grade 3-4 toxicities increase to 52.2-76.3% without improvement in survival outcomes, suggesting careful patient selection is critical 12, 3.
Combination with Biologics
When FOLFIRI is combined with bevacizumab, ramucirumab, or cetuximab, additional toxicities specific to the biologic agent must be anticipated 1, 2, 13.
Critical Monitoring Parameters
Monitor closely for:
- Early-onset diarrhea (cholinergic, within 24 hours)
- Late-onset diarrhea (days 5-10, potentially life-threatening)
- Neutropenia nadir (typically days 7-10)
- Dehydration secondary to GI toxicities
The toxicity profile is manageable with appropriate supportive care and dose modifications, making FOLFIRI a standard second-line option for metastatic colorectal cancer after oxaliplatin-based first-line therapy 2, 11, 14.